Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$32.81 USD

32.81
2,780,141

+0.16 (0.49%)

Updated May 17, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (190 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Research Reports for UnitedHealth Group, Coca-Cola & Roche Holding

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), The Coca-Cola Company (KO) and Roche Holding AG (RHHBY).

Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?

by Zacks Equity Research

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base

by Zacks Equity Research

The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.

Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance

by Zacks Equity Research

Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.

Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe

by Zacks Equity Research

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.

Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update

by Zacks Equity Research

Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.

Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

by Zacks Equity Research

FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.

Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.

Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device

by Zacks Equity Research

Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.

DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day.

Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) hemophilia B gene therapy resulted in a 71% reduction in annualized bleed rate (ABR) compared to standard-of-care treatment.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Gives Nod to RHHBY's Lunsumio, Accepts PFE Vaccine BLA

by Kinjel Shah

FDA approves Roche's (RHHBY) Lunsumio for follicular lymphoma and accepts Pfizer's (PFE) BLA for the pentavalent meningococcal vaccine candidate.

Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma

by Zacks Equity Research

Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.

Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.

Roche's (RHHBY) Hemophilia A Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Roche (RHHBY) receives a positive CHMP recommendation for label expansion of the hemophilia A drug Hemlibra in the European Union (EU).

The Zacks Analyst Blog Highlights Chevron, Roche Holding, General Electric, Centene and Carrier Global

by Zacks Equity Research

Chevron, Roche Holding, General Electric, Centene and Carrier Global are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Chevron, Roche & General Electric

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Roche Holding AG (RHHBY) and General Electric Company (GE).

Regeneron (REGN) Presents Positive Data on MM and FL Drugs

by Zacks Equity Research

Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.

Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study

by Zacks Equity Research

Exelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint. It also releases initial data from the QUARTZ-101 study.

Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

by Zacks Equity Research

Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

by Zacks Equity Research

Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.

Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug

by Zacks Equity Research

Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.

Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects

by Zacks Equity Research

Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.

Biogen (BIIB) Down on Report of Death in Alzheimer's Study

by Zacks Equity Research

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.

Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.